In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

Q1 2025 insights from Corvus Pharmaceuticals highlight promising soquelitinib trial results, extended funding, and plans for Phase 2 trials.